A recent FDA inspection of the company’s compounding facilities revealed unsanitary procedures that may put patients at risk of serious infection, though neither the FDA nor Unique Pharmaceuticals have received reports of contamination or patient infection.
The FDA release recommended healthcare professionals at ambulatory surgery centers and hospitals with unused, sterile products from Unique Pharmaceuticals should not administer them to patients. Recall instructions and a complete list of recalled products are available at Unique Pharmaceuticals’ website.
More Articles on Accreditation:
Eisenberg Award applications open August 1
4 tips for preparing for Joint Commission accreditation surveys
AAAHC: 4 tips for building an infection control program
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.